Publication: Metabolism and disposition of ataluren after oral administration to mice, rats, dogs, and humans
This research article, published in Drug Metabolism and Disposition, looks at the in vivo metabolism of ataluren in selected species
The metabolism of ataluren, a novel carboxylic acid–containing small molecule drug used for the treatment of diseases resulting from nonsense mutation Duchenne muscular dystrophy (nmDMD), is discussed
Absorption and disposition in vivo data from investigations in mice, rats, dogs, and healthy humans are presented
The mechanisms for ataluren metabolism are outlined
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Kong R, Ma J, Hwang S, et al.Drug Metab Dispos. 2020;48:317–325
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-DMD-0442 | October 2021
Sign in or register to access exclusive content on this site